A clinical study of DefenCath in pediatric patients
Latest Information Update: 20 May 2021
At a glance
- Drugs Citrate/heparin/taurolidine (Primary)
- Indications Catheter infections
- Focus Registrational; Therapeutic Use
- Sponsors CorMedix
- 20 May 2021 New trial record
- 13 May 2021 According to a CorMedix media release, the company expects to initiate this study when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed.